Literature DB >> 15072169

Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage.

J Fujita1, Y Ohtsuki, S Bandoh, H Takashima, Y Ueda, F Wu, Y Tojo, A Kubo, T Ishida.   

Abstract

Cytokeratin 19 fragment (CYFRA 21-1) level in serum have already been documented as a useful tumor marker for lung cancer. In the present study, we hypothesized that CYFRA 21-1 increases in the sera of patients with radiation pneumonitis, resulting from epithelial cell damage. We measured CYFRA 21-1 in the sera of patients with radiation pneumonitis and evaluated the correlation between CYFRA 21-1 level and severity of radiation pneumonitis as well as clinical course. We studied 16 patients diagnosed with radiation pneumonitis associated with primary lung cancer. CYFRA 21-1 levels in the sera of patients with diffuse radiation pneumonitis (n = 6) significantly increased compared to normal smokers (n = 10) or patients with local radiation pneumonitis (n = 10). CYFRA 21-1 values in sera changed according to the progression or improvement of the diffuse radiation pneumonitis. An immunohistochemical study using pulmonary tissues obtained from autopsied patients with radiation pneumonitis demonstrated that the hyaline membrane and proliferating type II pneumocytes were strongly stained by the anti-human cytokeratin 19 antibody. Our data demonstrated that CYFRA 21-1 was increased in patients with diffuse radiation pneumonitis. Since CYFRA 21-1 is widely used as a tumor marker for lung cancer, this evidence should be noted especially in irradiated patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072169     DOI: 10.1016/j.rmed.2003.10.010

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

Review 1.  Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung).

Authors:  Victor Y Yazbeck; Liza Villaruz; Marsha Haley; Mark A Socinski
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

2.  Idiopathic pulmonary fibrosis is associated with circulating antiepithelial antibodies.

Authors:  Ahmed Fahim; Mei C Chong; Michael G Crooks; Simon P Hart
Journal:  Lung       Date:  2012-05-16       Impact factor: 2.584

3.  The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.

Authors:  Lili Yu; Xiaoqing Lin; Liangming Zhang; Qingwei Wu; Songgao Zhang; Dunyan Chen; Xiaojie Pan; Yi Huang
Journal:  Int J Med Sci       Date:  2020-06-21       Impact factor: 3.738

4.  Combination of Serum miRNAs with Serum Exosomal miRNAs in Early Diagnosis for Non-Small-Cell Lung Cancer.

Authors:  Qingwei Wu; Lili Yu; Xiaoqing Lin; Qingzhu Zheng; Songgao Zhang; Dunyan Chen; Xiaojie Pan; Yi Huang
Journal:  Cancer Manag Res       Date:  2020-01-21       Impact factor: 3.989

5.  Fucosylated exosomal miRNAs as promising biomarkers for the diagnosis of early lung adenocarcinoma.

Authors:  Xiongfeng Chen; Lili Yu; Kun Hao; Xiaoqing Yin; Mingshu Tu; Liqing Cai; Liangming Zhang; Xiaojie Pan; Qi Gao; Yi Huang
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

6.  Identification of Serological Biomarkers for Early Diagnosis of Lung Cancer Using a Protein Array-Based Approach.

Authors:  Jianbo Pan; Guang Song; Dunyan Chen; Yadong Li; Shuang Liu; Shaohui Hu; Christian Rosa; Daniel Eichinger; Ignacio Pino; Heng Zhu; Jiang Qian; Yi Huang
Journal:  Mol Cell Proteomics       Date:  2017-10-11       Impact factor: 5.911

7.  New Immunosensing-Fluorescence Detection of Tumor Marker Cytokeratin-19 Fragment (CYFRA 21-1) Via Carbon Quantum Dots/Zinc Oxide Nanocomposite.

Authors:  Nawal Ahmed Alarfaj; Maha Farouk El-Tohamy; Hesham Farouk Oraby
Journal:  Nanoscale Res Lett       Date:  2020-01-15       Impact factor: 4.703

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.